Please login to the form below

Not currently logged in
Email:
Password:

prostate cancer

This page shows the latest prostate cancer news and features for those working in and with pharma, biotech and healthcare.

AZ/Merck's Lynparza improves survival in certain prostate cancers

AZ/Merck's Lynparza improves survival in certain prostate cancers

The phase 3 PROfound trial studied Lynparza in men with metastatic castration-resistant prostate cancer (mCRPC) with BRCA 1/2 or ATM gene mutations versus new hormonal agent (NHA) treatments enzalutamide ... These results help to transform the treatment

Latest news

  • Policy and public health COVID-19 by the numbers

    This is more than all the new cases of prostate cancer (N=64, 955) or breast cancer (N=56, 162) in the entire country of France in 2018 for an entire ... year. Global cancer observatory. 2, 3 and 4. The rate of doubling (in days) of COVID-19 for 5

  • Bayer gets EU nod for prostate cancer drug Nubeqa Bayer gets EU nod for prostate cancer drug Nubeqa

    prostate cancer when compared to placebo and ADT alone,” said Melissa Rowe, director of medical affairs for speciality medicine at Bayer UK. ... This authorisation represents a meaningful advancement in the fight against prostate cancer,” she added.

  • FDA accepts review to broaden GSK’s Zejula label FDA accepts review to broaden GSK’s Zejula label

    Other competitors in the class include Pfizer’s Talzenna (talazoparib) and Clovis’ Rubraca (rucaparib) – the latter of which recently beat its rivals to the punch in prostate cancer, for which is ... with advanced ovarian cancer who have already

  • Exelixis bounces back with new prostate cancer data Exelixis bounces back with new prostate cancer data

    The COSMIC-021 trial evaluated the combination treatment in patients with locally advanced or metastatic castration-resistant prostate cancer (CRPC), whose disease had progressed on prior novel hormone therapy. ... Exelixis previously attempted to tackle

  • Givlaari, Rybelsus lead crowded CHMP recommendations Givlaari, Rybelsus lead crowded CHMP recommendations

    Other notable recommendations include Bayer’s Nubeqa (darolutamide), which has been recommended for approval as a treatment for prostate cancer. ... Nubeqa will go head-to-head in the non-metastatic castration-resistant prostate cancer market with

More from news
Approximately 62 fully matching, plus 297 partially matching documents found.

Latest Intelligence

  • Surviving cancer: a new era for patients Surviving cancer: a new era for patients

    This treatment quickly became the ‘gold standard’ for women with metastatic breast cancer. ... In European patients, the average five-year relative survival rate was 83% for melanoma, 83% for prostate cancer, 82% for breast cancer and 57% for colon

  • Can protein degraders unlock ‘undruggable’ drug targets? Can protein degraders unlock ‘undruggable’ drug targets?

    1 trial of its lead candidate ARV-110 in prostate cancer earlier this year, ahead of rival biotechs such as C4 Therapeutics and Kymera Therapeutics as well as big pharma firms ... keep it inhibited – and which also run the risk of cancer cells

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    That includes potential new approvals for PARP inhibitor Lynparza in prostate and pancreatic cancer to extend its existing use in ovarian and breast cancer. ... The company’s biggest play last year was licensing Daiichi Sankyo’s cancer candidate

  • Leading AstraZeneca’s return to growth in Europe Leading AstraZeneca’s return to growth in Europe

    Approvals in BRCA-mutated pancreatic and prostate cancer are also expected in the near future, two tumour types where currently physicians aren’t accustomed to using these tests. ... First we had ovarian cancer, then breast cancer, and our next steps

  • Biotech profile: Tom Evans, CEO, Vaccitech.

    You have a broad pipeline of candidates, including therapeutic vaccines, such as your vaccine for prostate cancer in phase 1. ... How big a role do you think therapeutic vaccines will play in future cancer treatment?

More from intelligence
Approximately 1 fully matching, plus 49 partially matching documents found.

Latest appointments

  • Dendreon appoints new R&D lead Dendreon appoints new R&D lead

    urologists who are uniquely positioned to deliver long-term care to men with prostate cancer. ... stage prostate cancer, with the hope of curing more men of the disease.”.

  • Astellas bolsters oncology clinical development leadership Astellas bolsters oncology clinical development leadership

    breast cancer, leukaemia, lung cancer and prostate cancer. ... of Medicine and the University of Texas MD Anderson Cancer Center.

  • Astellas promotes John Demaree Astellas promotes John Demaree

    Demaree was promoted from his position as executive director of oncology marketing, where he oversaw the launch of prostate cancer drug Xtandi (enzalutamide) and promotion of lung cancer therapy Tarceva (erlotinib). ... Mark Reisenauer, senior vice

  • MDxHealth creates new global commercial team MDxHealth creates new global commercial team

    MDxHealth has created a new global commercial team to drive the launch of SelectMDx, its new prostate cancer test. ... the commercialisation of a molecular diagnostic test for prostate cancer across Europe.”.

  • Dr Hamina Patel moves from J&J to Evgen Pharma Dr Hamina Patel moves from J&J to Evgen Pharma

    She joins the firm from Johnson and Johnson, where she was director of drug development, oncology, where she helped to build a broad portfolio of indications for its cancer drug Velcade. ... interest in prostate cancer.

More from appointments
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 6 fully matching, plus 18 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics